Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Minneapolis, Minnesota Clinical Trials

A listing of Minneapolis, Minnesota clinical trials actively recruiting patient volunteers.

RESULTS

Found (1091) clinical trials

Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant

PRIMARY OBJECTIVES: I. Determine whether 2-5 year hematopoietic cell transplant (HCT) survivors with elevated cancer-related distress or poor health care adherence, adherence to cardiometabolic or subsequent malignancy surveillance who are randomized to receive the online, patient-centered, self-management stepped care program will report reduced distress, and improved health care adherence for ...

Phase N/A

0.0 miles

Learn More »

Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma

Multiple myeloma (MM) is the second most common hematologic malignancy in adults. Overall survival (OS) in MM has improved significantly in the last 15 years with the emergence of novel therapies such as thalidomide, bortezomib and lenalidomide. The median life expectancy of patients with MM treated in the current era ...

Phase N/A

0.0 miles

Learn More »

Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

Patients with primary MF (PMF), post-essential thrombocythemia (ET) MF, or post-polycythemia vera (PV) MF, with intermediate-2 or high-risk disease as determined by the DIPSS, and aged 55 at the time of DIPSS assessment are eligible for this study. For the allogeneic HCT arm of the HLA-Matched Donor HCT Study, donors ...

Phase N/A

0.0 miles

Learn More »

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation ...

Phase

0.05 miles

Learn More »

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

This is a randomized phase II study assessing the activity of single agent chemotherapy combined with nivolumab (Arm A) compared to single agent chemotherapy alone (Arm B) in squamous or non-squamous NSCLC subjects with primary resistance to prior PD-1 or PDL-1 inhibitor. The single agent chemotherapy chosen is at the ...

Phase

0.33 miles

Learn More »

VIVID - Valvular and Ventricular Improvement Via iCoapsys Delivery - Feasibility Study

Functional MR is a frequent outcome of ischemic heart disease or dilated cardiomyopathy. Patients with functional MR generally have normal valvular structures complicated by left ventricular dysfunction. Left ventricular dysfunction will often create geometric distortions that prevent complete leaflet coaptation, rendering the valve incompetent. Changes that will induce functional MR ...

Phase

0.33 miles

Learn More »

Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)

COPD is a disease in which the lung airways are damaged and partly obstructed, making it difficult to breathe. Millions of people in the United States have COPD, and it is the third leading cause of death in the United States. Symptoms include coughing, excess mucus production, shortness of breath, ...

Phase N/A

0.33 miles

Learn More »

Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Hypothesis The primary hypothesis is that metoprolol succinate will reduce the risk of COPD exacerbations as compared to placebo. The secondary hypothesis is that metoprolol succinate will not adversely impact lung function, exercise tolerance, dyspnea or quality of life as compared to placebo. Study Flow Patients will be screened and ...

Phase

0.33 miles

Learn More »

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

The programmed death ligand 1 (PD-L1) [16] and VEGFR2 [34] are highly-expressed on mesothelioma cells, and are therefore attractive options for this cancer. We chose to study the combination of ramucirumab with nivolumab because of the potential efficacy of these two agents in mesothelioma and because of the potential synergistic ...

Phase

0.33 miles

Learn More »

A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Phase

0.43 miles

Learn More »